about
Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan.Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancerClinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancersAnalysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclin D1.Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer.VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide.Metronomic chemotherapy for metastatic prostate cancer: a 'young' concept for old patients?Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity.Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration.Genetic interaction of P2X7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients.Melanocortin Receptor-4 Gene Polymorphisms in Glioblastoma Patients Treated with Concomitant Radio-Chemotherapy.Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward.Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth.Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib.CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1.CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells.Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo.VEGF-A polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration.First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study.EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan.The rs2071559 AA VEGFR-2 genotype frequency is significantly lower in neovascular age-related macular degeneration patients.IL-8 and VEGFR-2 polymorphisms modulate long-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration.Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients.Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab.
P50
Q33416977-B81F7357-833B-4997-9DC2-016262893AC8Q34173001-96EBDF81-212D-486A-A5BC-2C46496820CBQ34806780-30D66910-82F4-49BB-B97D-C49CE2C22FDBQ35918752-EEF4A521-E04B-4024-9B41-92267C177D73Q35966821-40B13005-C05D-4416-B00F-2CC82D08655DQ36282739-EC498316-1397-4148-85F8-E3E0B71832A6Q36618871-35D8982C-A361-4107-9EEE-BAA51DBD6FEAQ37111160-12AD2CE5-BB08-44DE-8D28-72D02442A989Q37784481-DBE5AF5D-0822-47DB-9F3D-C5A3422EBCC5Q37905064-D8CA2393-871E-4FB3-83DB-2A8A3CCBECC3Q38030051-F1A0FC21-2150-4506-8055-74CD1701C644Q38285850-2717DDBA-9345-4567-9360-C3F5EF0E8792Q38381406-D9F961A3-8041-4099-A762-3615C53B1A5EQ38582381-A30A5CDC-C9A7-48E8-AA19-8113D55E0795Q38722809-483D3407-09AC-43CF-A1F2-5A68FBC5FC18Q38889516-17243E04-82D9-4A31-94CD-A162C4D77C2AQ39034547-51995868-D7E7-40CF-8312-59C579244643Q39106511-F348AE22-CDEC-44FA-B689-D832581712F0Q39406065-1FD5B711-2774-470E-84F2-DB6C4F8CA70BQ39565751-3F916E86-B523-4437-9527-B2C491E56EB3Q39810346-5DB7AA58-3927-432E-9E0C-F211162AC26EQ41872813-2832921D-C888-40C6-8C4F-7F4D6FB41E59Q44857733-77B4CABF-E719-4951-B289-BB8B8EEEDF2AQ48686558-FE65DA73-9046-4158-AE42-B6CB70B4199EQ50862095-59F9E480-0AB1-4BA3-8E12-796E71856066Q51564245-0402B318-18B1-4BAA-BAEE-A009B1BD564AQ51611962-F8D19A99-4370-43FB-BA4F-EF68CAB66A75Q52852575-F3C0B496-EFF0-4FEE-A65D-27518016E6F3Q54180020-1AD4F45E-0A93-4101-9274-06C69ACD8942
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Teresa Di Desidero
@ast
Teresa Di Desidero
@en
Teresa Di Desidero
@es
Teresa Di Desidero
@sl
type
label
Teresa Di Desidero
@ast
Teresa Di Desidero
@en
Teresa Di Desidero
@es
Teresa Di Desidero
@sl
prefLabel
Teresa Di Desidero
@ast
Teresa Di Desidero
@en
Teresa Di Desidero
@es
Teresa Di Desidero
@sl
P106
P1153
35336305600
P2038
Teresa_Di_Desidero
P21
P214
1981148209327300460003
P31
P396
IT\ICCU\BVEV\218270
P496
0000-0002-5487-071X
P735
P7859
viaf-1981148209327300460003